EGFR and neoplasm: CAP and sorafenib showed similar efficacies in reducing the tumor size, combining CAP and sorafenib reached the best efficacy in controlling tumor growth, and treating tumors harboring the EGFR(Y1068F) mutation with CAP showed the same therapeutic outcome as the control (Figure 6I, 6J).